English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells

Bill, A., Schmitz, A., König, K., Heukamp, L. C., Hannam, J. S., & Famulok, M. (2012). Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells. PLoS One, 7(7), e41179. doi:10.1371/journal.pone.0041179.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-6417-D Version Permalink: http://hdl.handle.net/11858/00-001M-0000-0028-6418-B
Genre: Journal Article

Files

show Files
hide Files
:
Bill-2012-Anti-proliferative e.pdf (Any fulltext), 559KB
 
File Permalink:
-
Name:
Bill-2012-Anti-proliferative e.pdf
Description:
-
Visibility:
Private
MIME-Type / Checksum:
application/pdf
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show
hide
Description:
-
Description:
-

Creators

show
hide
 Creators:
Bill, A., Author
Schmitz, A., Author
König, K., Author
Heukamp, L. C., Author
Hannam, J. S., Author
Famulok, M.1, Author
Affiliations:
1External Organizations, ou_persistent22              

Content

show
hide
Free keywords: Animals Carcinoma, Non-Small-Cell Lung/*drug therapy Cell Line, Tumor Cell Proliferation Cytoplasm/metabolism *Drug Resistance, Neoplasm Drug Screening Assays, Antitumor/methods Gene Expression Regulation, Neoplastic Guanine Nucleotide Exchange Factors/*antagonists & inhibitors Humans Lung Neoplasms/*drug therapy Male Mice Mice, Nude Neoplasm Transplantation Quinazolines/*pharmacology Receptor, Epidermal Growth Factor/metabolism Receptor, IGF Type 1/metabolism Signal Transduction Triazoles/pharmacology
 Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been proven to efficiently inhibit the proliferation of a subset of non small-cell lung cancers (NSCLC). Unfortunately, the majority of NSCLC expressing wild type EGFR is primarily resistant to EGFR-TKI treatment. Here, we show that the proliferation of the gefitinib-resistant NSCLC cell lines H460 and A549 is reduced by the small molecule SecinH3 which indirectly attenuates EGFR activation by inhibition of cytohesins, a class of recently discovered cytoplasmic EGFR activators. SecinH3 and gefitinib showed a synergistic antiproliferative effect, which correlated with a profound inhibition of Akt activation and survivin expression. Treating mice bearing H460 xenografts with SecinH3 showed the antiproliferative and pro-apoptotic effect of SecinH3 in vivo. Our data suggest that targeting the EGFR indirectly by inhibiting its cytoplasmic activators, the cytohesins, has the potential to improve the treatment of primarily EGFR-TKI resistant lung cancers.

Details

show
hide
Language(s):
 Dates: 2012
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: Other: 22815959
DOI: 10.1371/journal.pone.0041179
ISSN: 1932-6203 (Electronic)
ISSN: 1932-6203 (Linking)
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: PLoS One
  Alternative Title : PloS one
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 7 (7) Sequence Number: - Start / End Page: e41179 Identifier: -